Suppr超能文献

将LLC-PK1肾上皮细胞表征为研究蛋白质药物肾小管重吸收的体外模型。

Characterization of LLC-PK1 kidney epithelial cells as an in vitro model for studying renal tubular reabsorption of protein drugs.

作者信息

Takakura Y, Morita T, Fujikawa M, Hayashi M, Sezaki H, Hashida M, Borchardt R T

机构信息

Department of Drug Delivery Research, Kyoto University, Japan.

出版信息

Pharm Res. 1995 Dec;12(12):1968-72. doi: 10.1023/a:1016256325921.

Abstract

PURPOSE

The purpose of this study was to assess whether LLC-PK1 renal epithelial cells could serve as an in vitro model for studying the renal tubular reabsorption of protein drugs.

METHODS

The association of 111In-labeled model protein drugs, bovine serum albumin (BSA), superoxide dismutase (SOD), soybean trypsin inhibitor (STI), and [Asu1.7]-eel calcitonin (Asu-ECT), with the monolayers of LLC-PK1 renal epithelial cells was characterized under various conditions.

RESULTS

The cellular association of these proteins was temperature-dependent and varied according to the protein. Saturation kinetics were observed for STI association, with the apparent Km and Vmax values determined to be 66.3 micrograms/ml and 250 ng/mg protein/min, respectively. The association of STI decreased with increases in medium pH from 5.4 to 8.4 and was inhibited significantly by 2,4-dinitrophenol, sodium azide, cytochalasin B, and colchicine, suggesting that the cellular association involved endocytosis. Mutual inhibition was observed in competitive binding experiments with the four protein drugs, suggesting that they shared a common binding site on the luminal membrane of LLC-PK1 cells. Taken together, these findings show that a variety of protein drugs bind to LLC-PK1 cells in a non-specific manner and possibly undergo endocytosis, a phenomenon that is similar to in vivo proximal tubular reabsorption.

CONCLUSIONS

LLC-PK1 renal epithelial cells would be a suitable model system for the study of the renal proximal tubular reabsorption of protein drugs.

摘要

目的

本研究旨在评估LLC-PK1肾上皮细胞是否可作为研究蛋白药物肾小管重吸收的体外模型。

方法

在不同条件下,对111In标记的模型蛋白药物牛血清白蛋白(BSA)、超氧化物歧化酶(SOD)、大豆胰蛋白酶抑制剂(STI)和[Asu1.7]-鳗鱼降钙素(Asu-ECT)与LLC-PK1肾上皮细胞单层的结合进行了表征。

结果

这些蛋白质的细胞结合具有温度依赖性,且因蛋白质而异。观察到STI结合的饱和动力学,其表观Km和Vmax值分别确定为66.3微克/毫升和250纳克/毫克蛋白质/分钟。随着培养基pH从5.4增加到8.4,STI的结合减少,并受到2,4-二硝基苯酚、叠氮化钠、细胞松弛素B和秋水仙碱的显著抑制,表明细胞结合涉及内吞作用。在四种蛋白药物的竞争性结合实验中观察到相互抑制,表明它们在LLC-PK1细胞的腔膜上共享一个共同的结合位点。综上所述,这些发现表明,多种蛋白药物以非特异性方式与LLC-PK1细胞结合,并可能经历内吞作用,这一现象类似于体内近端肾小管重吸收。

结论

LLC-PK1肾上皮细胞将是研究蛋白药物近端肾小管重吸收的合适模型系统。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验